Real-World Healthcare Resource Utilization (HRU) and Costs of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Receiving Eculizumab in a US Population

被引：0
|
作者：
Wendy Y. Cheng
Sujata P. Sarda
Nikita Mody-Patel
Sangeeta Krishnan
Mihran Yenikomshian
Malena Mahendran
Dominique Lejeune
Louise H. Yu
Mei Sheng Duh
机构：
[1] Analysis Group,
[2] Inc.,undefined
[3] Apellis Pharmaceuticals,undefined
[4] Inc.,undefined
[5] Groupe d’analyse,undefined
[6] Ltée,undefined
来源：
Advances in Therapy | 2021年 / 38卷
关键词：
Paroxysmal nocturnal hemoglobinuria; Eculizumab; Blood transfusion; Treatment patterns; Healthcare resource utilization; Medical costs; Absenteeism; Economic burden; Retrospective study;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：4461 / 4479
页数：18
相关论文
共 50 条
  • [41] MODELING AND SIMULATIONS OF ECULIZUMAB IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) AND ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS) PATIENTS
    Lathia, C.
    Kassir, N.
    Mouksassi, M. S.
    Jayaraman, B.
    Marier, J. F.
    Bedrosian, C. L.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 95 : S2 - S2
  • [42] Effect of Reducing Intravascular Hemolysis on Ferritin Homeostasis in Eculizumab Treated Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients
    Roeth, Alexander
    Schubert, Joerg
    Hock, Christina
    Christoph, Sandra
    Duehrsen, Ulrich
    [J]. BLOOD, 2008, 112 (11) : 1179 - 1179
  • [43] Longitudinal analysis of the monospecific coombs test in patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) chronically treated with Eculizumab
    Konik, A.
    Duehrsen, U.
    Roeth, A.
    [J]. ONKOLOGIE, 2010, 33 : 50 - 50
  • [44] Outcome characteristics of patients with paroxysmal nocturnal hemoglobinuria (PNH): data from the German PNH registry including eculizumab, ravulizumab and untreated patients
    Roth, A.
    Alashkar, F.
    Panse, J.
    Sockel, K.
    Haferlach, T.
    Hubel, K.
    Blau, I. W.
    Platzbecker, U.
    Hochsmann, B.
    Schrezenmeier, H.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 174 - 174
  • [45] REAL WORLD HEALTHCARE RESOURCE UTILIZATION (HRU) COSTS OF DIAGNOSTIC REVISION AMONG PATIENTS WITH PERIPHERAL T-CELL LYMPHOMAS (PTCL) IN THE US
    Rebeira, M.
    Bonafede, M.
    McMorrow, D.
    Park, J.
    Feliciano, J.
    Lisano, J.
    Richhariya, A.
    [J]. VALUE IN HEALTH, 2019, 22 : S72 - S72
  • [46] EFFECT OF ECULIZUMAB IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) PATIENTS WITH OR WITHOUT HIGH DISEASE ACTIVITY: RESULTS FROM THE INTERNATIONAL PNH REGISTRY
    Hoechsmann, B.
    de Fontbrune, F. Sicre
    Lee, J. W.
    Kulagin, A.
    Hillmen, P.
    Wilson, A.
    Marantz, J.
    Schrezenmeier, H.
    [J]. HAEMATOLOGICA, 2017, 102 : 188 - 189
  • [47] Treatment patterns, healthcare resource utilization, and healthcare costs among patients with pulmonary arterial hypertension in a real-world US database
    Studer, Sean
    Hull, Michael
    Pruett, Janis
    Koep, Eleena
    Tsang, Yuen
    Drake, William, III
    [J]. PULMONARY CIRCULATION, 2018, 9 (01)
  • [48] REAL-WORLD TREATMENT PATTERNS AND HEALTHCARE RESOURCE UTILIZATION (HRU) IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC)
    Bhanegaonkar, A.
    Gauthier, G.
    Kim, R.
    Vekeman, F.
    Dea, K.
    Robitaille, M. N.
    Moyneur, E.
    Liu, F. X.
    [J]. VALUE IN HEALTH, 2020, 23 : S84 - S84
  • [49] Real-world healthcare costs and resource utilization in patients with von Willebrand disease and angiodysplasia
    Connell, N. T.
    Caicedo, J.
    Nieto, N.
    Chatterjee, S.
    Hait, A.
    Gupta, A. K.
    Bullano, M.
    Schultz, B. G.
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2023, 23 (06) : 691 - 699
  • [50] Treatment Patterns and Healthcare Resource Utilization of Patients With Paroxysmal Nocturnal Hemoglobinuria: A Retrospective Claims Data Analysis
    Clayton, Denise
    Shafrin, Jason
    Yen, Glorian
    Lee, Soyon
    Geevarghese, Lincy
    Shi, Yulin
    He, Luyang
    Shen, Ying
    Waheed, Anem
    [J]. CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2024, 30
12345